Ask AI
ProCE Banner Activity

Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives

Podcast

This podcast examines evidence guiding the use of anti-CD38–based therapy in smoldering and newly diagnosed multiple myeloma, including risk stratification, transplant eligibility, frailty, and measurable residual disease assessments. Pharmacists review findings from pivotal trials of daratumumab- and isatuximab-containing regimens, discuss triplet and quadruplet treatment strategies for transplant-eligible and transplant-ineligible patients, and consider the evolving roles of transplantation, maintenance therapy, and response-adapted care. The discussion also addresses pharmacist-led supportive care, toxicity prevention and management, dose modification, and subcutaneous anti-CD38 administration to support individualized treatment selection and safe, sustained therapy.

Released: August 12, 2026

Review Activity

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients with high-risk smoldering MM on the latest evidence and expert guidance on anti-CD38–based treatment to support informed shared decision-making

  • Recommend individualized treatment strategies leveraging anti-CD38–based quadruplets for appropriate patients with newly diagnosed symptomatic MM based on the latest clinical evidence, expert recommendations, and patient/disease factors

  • Apply pharmacist-led strategies to mitigate and manage adverse events related to anti-CD38–based treatments for MM

Financial Disclosures

Primary Author

James A. Davis, PharmD, BCOP: consultant/advisor/speaker: Bristol Myers Squibb, GSK, Janssen.

Kelley L. Julian, PharmD, BCOP: consultant/advisor/speaker: GSK, Johnson & Johnson, Pfizer.